CD8A and neoplasm: Therefore, we hypothesized that a combination aGITR/aPD-1 therapy with vaccination would induce the expansion of tumor-reactive CD8 T cells and thus elicit sufficient tumor control and regression in a poorly immunogenic tumor model.